Innovent Biologics has received acceptance from China’s National Medical Products Administration (NMPA) to review its sintilimab and Nolgileucel injection (GC101) combination for advanced melanoma.
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.
Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its AI drug development platform.
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults.
Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.
10x Genomics has entered into a multi-project research agreement with Fred Hutchinson Cancer Center (Fred Hutch) for advancing single cell as well as spatial platforms in solid tumours and blood cancers.
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) across selected Latin American markets.
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and antibody-drug conjugates (ADCs) across multiple tumour types.
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.